Updated On: 28 December, 2021 10:32 AM IST | London | Agencies
Expert says, although RNA jabs produce more obvious and rapid jump in antibody levels in lab tests, other vaccines may be better at priming another part of the immune system – cellular immunity

A person receives a jab in a vaccination centre set up at Grim’s Dyke Golf Club in London on Sunday. Pic/AFP
Britain’s early deployment of the Oxford/AstraZeneca vaccine to protect against COVID-19 may be responsible for the country’s lower death rates compared to other European countries, a UK vaccines expert has said.
Dr Clive Dix, former chairman of the UK’s Vaccine Task Force, told the ‘Daily Telegraph’ that the Oxford/AstraZeneca vaccine – manufactured and administered in India as Covishield – may offer stronger long-term protection against severe COVID-19 and death.